Adimab

Adimab is the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies. The company operates a human antibody discovery platform based on synthetic and natural immune repertoires that are propagated and screened in their proprietary yeast system. Their technology enables the selection of key antibody properties in real-time, providing an advanced platform for antibody discovery and optimization.